Literature DB >> 25230937

Association between serotype-specific antibody response and serotype characteristics in patients with pneumococcal pneumonia, with special reference to degree of encapsulation and invasive potential.

Simon Athlin1, Margit Kaltoft2, Hans-Christian Slotved2, Björn Herrmann3, Hans Holmberg4, Helle Bossen Konradsen2, Kristoffer Strålin5.   

Abstract

We studied the immunoglobulin (Ig) response to causative serotype-specific capsular polysaccharides in adult pneumococcal pneumonia patients. The serotypes were grouped according to their degree of encapsulation and invasive potential. Seventy patients with pneumococcal pneumonia, 20 of whom were bacteremic, were prospectively studied. All pneumococcal isolates from the patients were serotyped, and the Ig titers to the homologous serotype were determined in acute- and convalescent-phase sera using a serotype-specific enzyme-linked immunosorbent assay. The Ig titers were lower in bacteremic cases than in nonbacteremic cases (P < 0.042). The Ig titer ratio (convalescent/acute titer) was ≥2 in 33 patients, 1 to 1.99 in 20 patients, and <1 in 17 patients. Patients ≥65 years old had a lower median Ig titer ratio than did younger patients (P < 0.031). The patients with serotypes with a thin capsule (1, 4, 7F, 9N, 9V, and 14) and medium/high invasive potential (1, 4, 7F, 9N, 9V, 14, and 18C) had higher Ig titer ratios than did patients with serotypes with a thick capsule (3, 6B, 11A, 18C, 19A, 19F, and 23F) and low invasive potential (3, 6B, 19A, 19F, and 23F) (P < 0.05 for both comparisons after adjustment for age). Ig titer ratios of <1 were predominantly noted in patients with serotypes with a thick capsule. In 8 patients with pneumococcal DNA detected in plasma, the three patients with the highest DNA load had the lowest Ig titer ratios. In conclusion, a high antibody response was associated with serotypes with a thin capsule and medium/high invasive potential, although a low antibody response was associated with serotypes with a thick capsule and a high pneumococcal plasma load.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25230937      PMCID: PMC4248763          DOI: 10.1128/CVI.00259-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  38 in total

1.  Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods.

Authors:  M Aickin; H Gensler
Journal:  Am J Public Health       Date:  1996-05       Impact factor: 9.308

2.  Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S.

Authors:  S A Quataert; C S Kirch; L J Wiedl; D C Phipps; S Strohmeyer; C O Cimino; J Skuse; D V Madore
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

3.  Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons.

Authors:  H B Konradsen
Journal:  Clin Infect Dis       Date:  1995-09       Impact factor: 9.079

4.  Typing of pneumococci by using 12 pooled antisera.

Authors:  U B Sørensen
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

5.  Emergence of antibody to capsular polysaccharides of Streptococcus pneumoniae during outbreaks of pneumonia: association with nasopharyngeal colonization.

Authors:  D M Musher; J E Groover; M R Reichler; F X Riedo; B Schwartz; D A Watson; R E Baughn; R F Breiman
Journal:  Clin Infect Dis       Date:  1997-03       Impact factor: 9.079

6.  The prevalence of potential pathogenic bacteria in nasopharyngeal samples from healthy children and adults.

Authors:  R K Gunnarsson; S E Holm; M Söderström
Journal:  Scand J Prim Health Care       Date:  1998-03       Impact factor: 2.581

7.  The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

Authors:  E D Shapiro; A T Berg; R Austrian; D Schroeder; V Parcells; A Margolis; R K Adair; J D Clemens
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

Review 8.  Pneumococcal virulence factors and host immune responses to them.

Authors:  D A Watson; D M Musher; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-06       Impact factor: 3.267

9.  Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis.

Authors:  M J Fine; M A Smith; C A Carson; S S Mutha; S S Sankey; L A Weissfeld; W N Kapoor
Journal:  JAMA       Date:  1996-01-10       Impact factor: 56.272

10.  Natural and vaccine-related immunity to Streptococcus pneumoniae.

Authors:  D M Musher; A J Chapman; A Goree; S Jonsson; D Briles; R E Baughn
Journal:  J Infect Dis       Date:  1986-08       Impact factor: 5.226

View more
  6 in total

1.  Clinical and Microbiological Factors Associated with High Nasopharyngeal Pneumococcal Density in Patients with Pneumococcal Pneumonia.

Authors:  Helena Alpkvist; Simon Athlin; Pontus Nauclér; Björn Herrmann; Guma Abdeldaim; Hans-Christian Slotved; Jonas Hedlund; Kristoffer Strålin
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

Review 2.  Invasive pneumococcal disease caused by mucoid serotype 3 Streptococcus pneumoniae: a case report and literature review.

Authors:  Naomi Sugimoto; Yuka Yamagishi; Jun Hirai; Daisuke Sakanashi; Hiroyuki Suematsu; Naoya Nishiyama; Yusuke Koizumi; Hiroshige Mikamo
Journal:  BMC Res Notes       Date:  2017-01-04

3.  Serotypes With Low Invasive Potential Are Associated With an Impaired Antibody Response in Invasive Pneumococcal Disease.

Authors:  Nils Littorin; Fabian Uddén; Jonas Ahl; Fredrik Resman; Hans-Christian Slotved; Simon Athlin; Kristian Riesbeck
Journal:  Front Microbiol       Date:  2018-11-15       Impact factor: 5.640

4.  A Nonfunctional Opsonic Antibody Response Frequently Occurs after Pneumococcal Pneumonia and Is Associated with Invasive Disease.

Authors:  Fabian Uddén; Jonas Ahl; Nils Littorin; Kristoffer Strålin; Simon Athlin; Kristian Riesbeck
Journal:  mSphere       Date:  2020-02-05       Impact factor: 4.389

5.  Can PPSV-23 Vaccine Impact Exacerbations of Chronic Cough Symptoms and Medication Use in Younger Adult Asthmatics? A Clinical Question That Needs Answering.

Authors:  Alessandra M Lanz; Esther Chartrand; Claudia P Eisenlohr; Miguel J Lanz
Journal:  Vaccines (Basel)       Date:  2022-01-30

6.  Mucosal Infections and Invasive Potential of Nonencapsulated Streptococcus pneumoniae Are Enhanced by Oligopeptide Binding Proteins AliC and AliD.

Authors:  Jessica L Bradshaw; Haley R Pipkins; Lance E Keller; James K Pendarvis; Larry S McDaniel
Journal:  MBio       Date:  2018-01-16       Impact factor: 7.867

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.